• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Insulin Resistance - Pipeline Review, H2 2012 Product Image

Insulin Resistance - Pipeline Review, H2 2012

  • ID: 2366344
  • December 2012
  • 75 pages
  • Global Markets Direct

Insulin Resistance – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Insulin Resistance - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Insulin Resistance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Insulin Resistance. Insulin Resistance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Insulin Resistance.
- A review of the Insulin Resistance products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Insulin Resistance Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Insulin Resistance 9
Insulin Resistance Therapeutics under Development by Companies 11
Insulin Resistance Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Insulin Resistance Therapeutics – Products under Development by Companies 19
Insulin Resistance Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Insulin Resistance Therapeutics Development 22
Novartis AG 22
Genfit 23
N-Gene Research Laboratories, Inc. 24
Limerick BioPharma, Inc. 25
AUS Bio Limited 26
Insulin Resistance – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
GFT-505 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SERX-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
fenretinide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Atorvastatin + Pioglitazone - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BGP-15 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
anakinra - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
hydroxychloroquine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
somatropin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rosiglitazone maleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Human Growth Hormone + Avandia - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
salsalate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Resveratrol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pioglitazone hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
resveratrol - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
sildenafil citrate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BVS-857 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
metformin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MD-960 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Drug Acting On Hematopoietic AMPK Beta 1 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LIM-0705 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
telmisartan - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eplerenone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Metformin + Pegylated Interferon Alpha + Ribavirin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pioglitazone hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Metformin + Abiraterone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TRPV4 Program - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Insulin Resistance Therapeutics – Drug Profile Updates 64
Insulin Resistance Therapeutics – Discontinued Products 70
Insulin Resistance Therapeutics - Dormant Products 71
Insulin Resistance – Product Development Milestones 72
Featured News & Press Releases 72
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 72
Aug 19, 2010: Limerick BioPharma Announces Positive Phase 1b Data for LIM-0705 in Preventing Toxicities Associated with the Transplant Drug, Tacrolimus. 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products Under Development for Insulin Resistance, H2 2012 9
Products under Development for Insulin Resistance – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Novartis AG, H2 2012 22
Genfit, H2 2012 23
N-Gene Research Laboratories, Inc., H2 2012 24
Limerick BioPharma, Inc., H2 2012 25
AUS Bio Limited, H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Insulin Resistance Therapeutics – Drug Profile Updates 64
Insulin Resistance Therapeutics – Discontinued Products 70
Insulin Resistance Therapeutics – Dormant Products 71

List of Figures
Number of Products under Development for Insulin Resistance, H2 2012 9
Products under Development for Insulin Resistance – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos